Department of Medicine, University of California , Irvine, California.
Department of Physiology and Biophysics, University of California, Irvine, California.
Am J Physiol Gastrointest Liver Physiol. 2018 Aug 1;315(2):G241-G248. doi: 10.1152/ajpgi.00071.2018. Epub 2018 Apr 6.
Sodium-dependent vitamin C transporter-1 (SVCT-1) is the major transporter mediating intestinal vitamin C uptake. Intestinal inflammation and prolonged infection are associated with increased serum and intestinal mucosa levels of tumor necrosis factor-α (TNF-α), which also exerts profound effects on the intestinal absorption process. Elevated levels of TNF-α have been linked to the pathogenesis of inflammatory bowel disease (IBD) and malabsorption of nutrients, and patients with this condition have low levels of vitamin C. To date, little is known about the effect of TNF-α on intestinal absorption of vitamin C. We studied the impact of TNF-α on ascorbic acid (AA) transport using a variety of intestinal preparations. The expression level of human SVCT-1 mRNA is significantly lower in patients with IBD. TNF-α treated Caco-2 cells and mice showed a significant inhibition of intestinal C-AA uptake. This inhibition was associated with significant decreases in SVCT-1 protein, mRNA, and heterogeneous nuclear RNA levels in TNF-α treated Caco-2 cells, mouse jejunum, and enteroids. Also, TNF-α caused a significant inhibition in the SLC23A1 promoter activity. Furthermore, treatment of Caco-2 cells with celastrol (NF-κB inhibitor) blocked the inhibitory effect caused by TNF-α on AA uptake, SVCT-1 protein, and mRNA expression, as well as the activity of SLC23A1 promoter. Treatment of TNF-α also led to a significant decrease in the expression of hepatocyte nuclear factor-1-α, which drives the basal activity of SLC23A1 promoter, and this effect was reversed by celastrol. Together, these findings show that TNF-α inhibits intestinal AA uptake, and this effect is mediated, at least in part, at the level of transcription of the SLC23A1 gene via the NF-κB pathway. NEW & NOTEWORTHY Our findings show that tumor necrosis factor-α inhibits intestinal ascorbic acid uptake in both in vitro and in vivo systems, and this inhibitory effect is mediated, at least in part, at the level of transcription of the SLC23A1 (sodium-dependent vitamin C transporter-1) gene via the NF-κB pathway.
钠依赖性维生素 C 转运蛋白 1(SVCT-1)是介导肠道维生素 C 摄取的主要转运蛋白。肠道炎症和长期感染与血清和肠道黏膜中肿瘤坏死因子-α(TNF-α)水平升高有关,而 TNF-α 也对肠道吸收过程产生深远影响。TNF-α 水平升高与炎症性肠病(IBD)和营养物质吸收不良的发病机制有关,并且此类患者的维生素 C 水平较低。迄今为止,人们对 TNF-α 对肠道维生素 C 吸收的影响知之甚少。我们使用各种肠道制剂研究了 TNF-α 对抗坏血酸(AA)转运的影响。IBD 患者的人 SVCT-1mRNA 表达水平明显降低。TNF-α 处理的 Caco-2 细胞和小鼠的肠道 C-AA 摄取明显受到抑制。这种抑制与 TNF-α 处理的 Caco-2 细胞、小鼠空肠和类器官中的 SVCT-1 蛋白、mRNA 和异质核 RNA 水平的显著降低有关。此外,TNF-α 导致 SLC23A1 启动子活性显著抑制。此外,用塞拉托林(NF-κB 抑制剂)处理 Caco-2 细胞可阻断 TNF-α 对 AA 摄取、SVCT-1 蛋白和 mRNA 表达以及 SLC23A1 启动子活性的抑制作用。TNF-α 处理还导致肝细胞核因子-1-α的表达显著降低,该因子驱动 SLC23A1 启动子的基础活性,而塞拉托林可逆转这种作用。综上所述,这些发现表明 TNF-α 抑制肠道 AA 摄取,这种作用至少部分通过 NF-κB 途径在 SLC23A1 基因转录水平上介导。
我们的研究结果表明,肿瘤坏死因子-α在体外和体内系统中均抑制肠道抗坏血酸摄取,这种抑制作用至少部分通过 NF-κB 途径在 SLC23A1(钠依赖性维生素 C 转运蛋白-1)基因转录水平上介导。